292 related articles for article (PubMed ID: 15667866)
1. Genotypes of TNF-alpha, VEGF, hOGG1, GSTM1, and GSTT1: useful determinants for clinical outcome of bladder cancer.
Kim EJ; Jeong P; Quan C; Kim J; Bae SC; Yoon SJ; Kang JW; Lee SC; Jun Wee J; Kim WJ
Urology; 2005 Jan; 65(1):70-5. PubMed ID: 15667866
[TBL] [Abstract][Full Text] [Related]
2. Polymorphism of GSTM1 and GSTT1 genes in bladder cancer: a study from North India.
Srivastava DS; Kumar A; Mittal B; Mittal RD
Arch Toxicol; 2004 Aug; 78(8):430-4. PubMed ID: 15057507
[TBL] [Abstract][Full Text] [Related]
3. Polymorphism within the cyclin D1 gene is associated with an increased risk of carcinoma in situ in patients with superficial bladder cancer.
Ito M; Habuchi T; Watanabe J; Higashi S; Nishiyama H; Wang L; Tsuchiya N; Kamoto T; Ogawa O
Urology; 2004 Jul; 64(1):74-8. PubMed ID: 15245939
[TBL] [Abstract][Full Text] [Related]
4. Genetic variants of the cytochrome P450 and glutathione S-transferase associated with risk of bladder cancer in a south-eastern Chinese population.
Shao J; Gu M; Zhang Z; Xu Z; Hu Q; Qian L
Int J Urol; 2008 Mar; 15(3):216-21. PubMed ID: 18304215
[TBL] [Abstract][Full Text] [Related]
5. Polymorphic deletions of the GSTT1 and GSTM1 genes and susceptibility to bladder cancer.
Salinas-Sánchez AS; Sánchez-Sánchez F; Donate-Moreno MJ; Rubio-del-Campo A; Gimenez-Bachs JM; Lorenzo-Romero JG; Serrano-Oviedo L; Escribano J
BJU Int; 2011 Jun; 107(11):1825-32. PubMed ID: 20942828
[TBL] [Abstract][Full Text] [Related]
6. Association of genetic polymorphism of glutathione S-transferase M1, T1, P1 and susceptibility to bladder cancer.
Srivastava DS; Mishra DK; Mandhani A; Mittal B; Kumar A; Mittal RD
Eur Urol; 2005 Aug; 48(2):339-44. PubMed ID: 16005379
[TBL] [Abstract][Full Text] [Related]
7. Association of bladder tumors and GA genotype of -308 nucleotide in tumor necrosis factor-alpha promoter with greater tumor necrosis factor-alpha expression.
Jeong P; Kim EJ; Kim EG; Byun SS; Kim CS; Kim WJ
Urology; 2004 Nov; 64(5):1052-6. PubMed ID: 15533517
[TBL] [Abstract][Full Text] [Related]
8. Glutathione S-transferase M1, T1 and P1 polymorphisms: susceptibility and outcome in lung cancer patients.
Sreeja L; Syamala V; Hariharan S; Syamala VS; Raveendran PB; Sivanandan CD; Madhavan J; Ankathil R
J Exp Ther Oncol; 2008; 7(1):73-85. PubMed ID: 18472644
[TBL] [Abstract][Full Text] [Related]
9. The role of N-acetyltransferase-2 and glutathione S-transferase on the risk and aggressiveness of bladder cancer.
Giannakopoulos X; Charalabopoulos K; Baltogiannis D; Chatzikiriakidou A; Alamanos Y; Georgiou I; Evangelou A; Agnantis N; Sofikitis N
Anticancer Res; 2002; 22(6B):3801-4. PubMed ID: 12552997
[TBL] [Abstract][Full Text] [Related]
10. [Occupational and non-occupational risk factors in bladder cancer patients in an industrialized area located in former East-Germany].
Golka K; Seidel T; Dietrich H; Roth G; Rötzel C; Thier R; Geller F; Reckwitz T; Schulze H
Aktuelle Urol; 2005 Sep; 36(5):417-22. PubMed ID: 16163604
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms of N-acetyltransferase 2, glutathione S-transferase mu and theta genes as risk factors of bladder cancer in relation to asthma and tuberculosis.
Kim WJ; Lee HL; Lee SC; Kim YT; Kim H
J Urol; 2000 Jul; 164(1):209-13. PubMed ID: 10840461
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms of glutathione S-transferase μ and θ, MDR1 and VEGF genes as risk factors of bladder cancer: a case-control study.
Henríquez-Hernández LA; Navarro P; Luzardo OP; Alvarez-León EE; Boada LD; Zumbado M; Pestano J; Suárez JR; Chesa N; Almeida M; Valerón PF
Urol Oncol; 2012 Sep; 30(5):660-5. PubMed ID: 21292509
[TBL] [Abstract][Full Text] [Related]
13. Analysis of hOGG1 genotype as a prognostic marker for muscle invasive bladder cancer: a novel approach using peptide nucleic acid-mediated, real-time PCR clamping.
Kim EJ; Yan C; Ha YS; Jeong P; Yi Kim I; Moon SK; Choi YH; Kim WJ
Urol Oncol; 2012 Sep; 30(5):673-9. PubMed ID: 20884250
[TBL] [Abstract][Full Text] [Related]
14. Possible correlation between polymorphism in the tumor necrosis factor-beta gene and the clinicopathological features of bladder cancer in Japanese patients.
Nonomura N; Tokizane T; Nakayama M; Inoue H; Nishimura K; Muramatsu M; Okuyama A
Int J Urol; 2006 Jul; 13(7):971-6. PubMed ID: 16882065
[TBL] [Abstract][Full Text] [Related]
15. hOGG1 Ser326Cys and XRCC1 Arg399Gln polymorphisms associated with chronic obstructive pulmonary disease.
Yang SF; Xu YJ; Xie JG; Zhang ZX
Chin Med J (Engl); 2009 Apr; 122(8):960-6. PubMed ID: 19493423
[TBL] [Abstract][Full Text] [Related]
16. The predictive value of GSTT1 polymorphisms in predicting the early response to induction BCG therapy in patients with non-muscle invasive bladder cancer.
Kang HW; Tchey DU; Yan C; Kim WT; Kim YJ; Yun SJ; Lee SC; Choi YH; Kim IY; Kim WJ
Urol Oncol; 2014 May; 32(4):458-65. PubMed ID: 24411789
[TBL] [Abstract][Full Text] [Related]
17. Glutathione S-transferase M1 and its variants A and B as host factors of bladder cancer susceptibility: a case-control study.
Brockmöller J; Kerb R; Drakoulis N; Staffeldt B; Roots I
Cancer Res; 1994 Aug; 54(15):4103-11. PubMed ID: 8033143
[TBL] [Abstract][Full Text] [Related]
18. Analysis of polymorphisms of tumor necrosis factor-alpha and polymorphic xenobiotic metabolizing enzymes in inflammatory bowel disease: study from northern India.
Mittal RD; Manchanda PK; Bid HK; Ghoshal UC
J Gastroenterol Hepatol; 2007 Jun; 22(6):920-4. PubMed ID: 17565649
[TBL] [Abstract][Full Text] [Related]
19. Glutathione S-transferase M1 genotypes and the risk of anal cancer: a population-based case-control study.
Chen C; Madeleine MM; Lubinski C; Weiss NS; Tickman EW; Daling JR
Cancer Epidemiol Biomarkers Prev; 1996 Dec; 5(12):985-91. PubMed ID: 8959321
[TBL] [Abstract][Full Text] [Related]
20. A single-nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances bladder cancer susceptibility.
Tasci AI; Tugcu V; Ozbek E; Ozbay B; Simsek A; Koksal V
BJU Int; 2008 Feb; 101(4):503-7. PubMed ID: 17986285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
